RAD June 2024 Abstracts and Posters
667 Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis
Jonathan I. Silverberg, Andreas Wollenberg, Franz J. Legat, Vivian T. Laquer, April W. Armstrong, Pedro Herranz6, Luigi Naldi, Faiz Ahmad, Liliana Ulianov, Christophe Piketty
668 Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)
Jonathan I Silverberg, Andreas Wollenberg, Franz J Legat, Vivian T Laquer, Liliana Ulianov, Soo Yeon Cheong, Anna Ryzhkova, Christophe Piketty
669 Characteristics of adult patients with atopic dermatitis initiating biologics and JAK inhibitors in the CorEvitas AD Registry
Eric Simpson, Christian Fenske, Alvin Li, Zach Dawson, Yolanda Muñoz Maldonado, Kaylee Ho, Kayla Callahan, Linda Stein Gold, Seemal Desai, Alexandra Golant, Douglas DiRuggiero, Jonathan I Silverberg
670 Tapinarof cream 1% once daily is efficacious for the treatment of atopic dermatitis in patients with skin of color down to 2 years of age in two pivotal phase 3 trials
Andrew F. Alexis, Leon Kircik, Raj Chovatiya, Zakiya P. Rice, Tina Bhutani, Philip M. Brown, Stephen C. Piscitelli, David S. Rubenstein, Anna M. Tallman, April W. Armstrong
671 Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis
Eric Simpson, Jonathan I. Silverberg, Robert Bissonnette, Linda Stein Gold, April W. Armstrong, Adelaide A. Hebert, Rocco T. Serrao, Jeannette R. Jakus, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna M. Tallman, Lawrence F. Eichenfield
672 Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies
Gil Yosipovitch, Sonja Ständer, Martin Metz, Andrew E. Pink, Jonathan I. Silverberg, Howard Sofen, Faiz Ahmad, Aliene Noda, Zarif K. Jabbar Lopez, Christophe Piketty, Shawn G. Kwatra
673 Efficacy of nemolizumab in different subgroups of patients with prurigo nodularis in two randomized, placebo-controlled phase 3 trials
Shawn G. Kwatra, Martin Metz, Andrew E. Pink, Gil Yosipovitch, Rola Gharib, Hema Sundaram, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar Lopez, Christophe Piketty, Sonja Ständer
674 Patient-reported outcomes for GSK1070806, an anti-IL-18 monoclonal antibody: a phase 1b, randomised, double-blind, parallel-group placebo-controlled study of patients with atopic dermatitis
Parima Ghafoori, PharmD, Lea Fortunato, PhD, Dharm S. Patel, PhD, Joanne Ellis, PhD, Gabriel Wong, MD, John B. Kelly, MD, PhD, Helen Birch, PhD, Wen-Hung Chen, PhD, Iain Uings, BSc
675 Dupilumab demonstrates higher likelihood of achieving improvements in signs, symptoms, and quality of life vs lebrikizumab: results from a placebo-adjusted indirect comparison analysis
Patricia Guyot, Yingxin Xu, Amy Praestgaard, Nick Freemantle, Ana B. Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian
676 Dupilumab increases levels of bone growth biomarker irrespective of prior use of systemic corticosteroids in children with moderate-to-severe atopic dermatitis
Alan D. Irvine, Amy S. Paller, Sara Hamon, Julie Horowitz, Annamaria Farrell, Sarah Hatsell, Peter Ehmann, Ainara Rodríguez Marco, Ashish Bansal, Zhen Chen, Stephane Levy, Sonya L. Cyr